Latest News

David gave a presentation to Manchester Metropolitan University as part of their Biomedical Away Day. His presentation was on the Opportunities and Challenges in collaborating between Universities and Industry.

Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4th April 2017. In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead compound, BB2603, a novel nanoparticle [...]

The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager and Jane Davies, Senior CRA, held their site initiation visit (SIV) at the Parexel Early Phase Clinical Unit in Berlin, [...]

Blueberry has now gained regulatory and ethical approval to run its first clinical trial using its novel nanoparticle delivered spray formulation to rapidly treat onychomycosis (OM) and associated tinea pedis (TP). We plan to start the trial early March. Dr John Ridden [...]

SHAMROK is the Sheffield Antimicrobial Resistance Network, which aims to bring together researchers at both the University and Industry to seek new solutions to the problems of multi-drug resistant infection. CSO David Cook gave a presentation about the challenges of [...]

Blueberry Therapeutics was pleased to host Dr. Sudax Murdan from University College London. Sudax is a world expert in disease of the nail and topical drug delivery. Sudax spent the day with the Blueberry team including her excellent seminar on [...]

CSO David Cook presents at the “Superbugs & Supderdrugs” conference held in Iselin, USA. The conference brought together experts in anti-microbial drug resistance from Government, Pharma and Biotech. David gave a presentation on “Targeting Mechanisms of Resistance Using Protein Resistance [...]

Blueberry Therapeutics today announced that it has raised £3 million to progress the development of its topical fungal infection therapies into human clinical trials. The investment was led by the GM&C Life Sciences Fund, managed by Catapult Ventures, and [...]

Blueberry was delighted to host HRH the Duke of York on Tuesday the 2nd of February when he visited our laboratories during a visit to Alderley Park as part of the “Pitch@Palace 5.0 tour (http://pitchatpalacenews.com)”. The Duke met with Julie [...]

Blueberry Therapeutics Ltd are amongst 80 co-signatories on a declaration at the World Economic Forum in Davos committing to working together to solve the growing issue of antimicrobial drug resistance and calling for governments to improve financial incentives and investment [...]

  Blueberry Therapeutics Ltd is delighted to have joined the BEAM Alliance (Biopharmaceutical companies from Europe in Anti-Microbial resistance). The BEAM Alliance aims to raise awareness on the very specific issues that small and medium European biopharmaceutical companies are facing when [...]

Blueberry Therapeutics and LSTM are awarded an MRC Confidence in Concept grant to explore nano-formulations of Ceftriaxone for the treatment of Typhoid fever. Dave Cook, Chief Scientific Officer at Blueberry said “We’re delighted to be working with the team at LSTM on this exciting project. [...]

  Blueberry are delighted to welcome Mr. Andrew Kay to Blueberry Therapeutics as Chairman of the Board. Andrew brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Andrew’s leadership, Algeta’s [...]

Blueberry Therapeutics are delighted to have won an SBRI NHS contract to progress their smart wound dressing technology through Feasibility studies. The contract will allow Blueberry to complete preclinical feasibility studies of a hydrogel based SMART wound dressing for the [...]

Both Dr John Ridden (CEO) and Dr Mike Davies (CMO) will be at Biotrinity from the 11th May through until 13th May. We are very much looking forward to meeting with old friends, colleagues, investors and attending as many of [...]

Blueberry today announced the successful completion of an investment round raising a total of $1.75M from both UK and Swiss based investors. The investment will help take its 2 most advanced programs through to regulatory approval stage. Dr Mike Davies, [...]

Blueberry Therapeutics today announced the launch of their new web site. John Ridden CEO and co-founder described the new site as a 'fresh clean communication route through which we can reach out to patients, collaborators and investors'. The new website [...]

Blueberry announces that it has started collaborating with The University of Sheffield and Sheffield Hallam University to explore development of new anti-fungal drugs and treatments. This collaborative project brings together leading academics at both of Sheffield’s world-class universities with Blueberry’s [...]

John Ridden presented a Keynote address at the MRC Workshop in London on the 25th November 2014. The topic of this important meeting 'Accelerating therapeutic and diagnostic development'. John commented that this meeting brings together a number of influential scientists [...]

David’s paper written with colleagues from AstraZeneca is entitled “Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework”  and is a comprehensive analysis of AstraZeneca’s portfolio between 2005-2010. The paper examines in detail the root-causes for drug project [...]

Blueberry begins a collaboration with the University of Manchester exploring the mode of action and therapeutic potential of novel antiflammatory agents.  Blueberry Therapeutics (Blueberry) today announced that it had started a collaboration with Professor Ian Kimber and Dr. Rebecca Dearman at [...]